Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopia [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating faricimab for choroidal neovascularization due to pathologic myopia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Choroidal Neovascularization Secondary to Pathologic Myopia

Drugs mentioned

• Faricimab (faricimab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Choroidal Neovascularization Secondary to Pathologic Myopia | Phase 3 | Status: COMPLETED